Replimune Inc. (REPL) - Rasio kapitalisasi marang bathi resik

Replimune Group, Inc. (REPL) focuses on developing oncolytic viruses, where the success of the RP1 platform will enable the scaling of drug production through partners to achieve high margins. This price chart featuring the -7.70 indicator complements the analysis. The company's position is strengthening due to successful tests, although the lack of revenue is accelerating the cash burn. The primary threats lie in potential trial failures and capital shortages.

REPL replimune.com: Koefisien rega marang bathi ing interval 04.07.2022 - 10.11.2026

Rincian analitis perusahaan Replimune Group, Inc.

- rega pasar lan target rega analis:

Rega bursa replimune.com|REPL - Prakiraan konsensus analis

- indikator kapitalisasi pasar:

Kapitalisasi pasar Replimune Group, Inc.|REPL - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data nilai buku modal saham:

Nilai Aset Bersih saben Saham Replimune|REPL - Aset Bersih Perusahaan|Nilai Pasar marang Nilai Buku replimune.com|REPL - Total Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

Koefisien Total Utang marang Modal Replimune Group, Inc.|REPL - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Replimune Inc.|REPL - Utang perusahaan|Utang marang nilai buku Replimune Group, Inc.|REPL - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Replimune|Rasio likuiditas darurat replimune.com

- data bathi bisnis lan rasio investasi:

REPL - Bathi resik perusahaan|Bathi resik sing dikarepake Replimune Group, Inc.|REPL - Koefisien rega marang bathi|Pangali forward rega marang bathi Replimune Group Inc|REPL - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Replimune Group, Inc.|REPL - Bathi operasional EBITDA|Bathi saben saham sajroning taun lumaku Replimune|REPL - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan replimune.com|REPL - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Replimune Group, Inc.

Analisis komprehensif perusahaan:REPL replimune.com

Produk asil prodhuksi Replimune Group, Inc.

The development of cancer immunotherapy based on the RP1 platform determines the P/E ratio dynamics for Replimune Group, Inc. (REPL). This ratio correlates the market value of the business with its annual net income, measuring the payback period for investments. The calculation is based on dividing market capitalization by earnings, reflecting current market expectations for the biotech's future success. The diversification of clinical trials reduces risks, making the investment valuation more resilient to volatility.

Perusahaan pesaing